Global Breast Cancer Market Report: 2015 Edition


#315089

64pages

Koncept Analytics

$ 800

In Stock

 

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

 

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

 

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

 

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report. 

 

1. Market Overview

1.1 Breast Cancer

1.2 Types of Breast Cancer

1.3 Risk Factors

1.4 Symptoms of Breast Cancer

1.5 Diagnosis and Treatment of Breast Cancer

1.5.1 Breast Cancer Screening and Diagnostic Measures

1.5.2 Breast Cancer Treatment

 

2. Breast Cancer Market

2.1 Global Market

  • Diagnostics Market
  • Therapeutic Market
  • Market Segmentation

3. Regional Markets

3.1 The U.S. Breast Cancer Market

3.1.1 The U.S. Breast Cancer Diagnostics Market

3.1.2 The U.S. Breast Cancer Therapeutic Market

3.1.3 The U.S. Metastatic Breast Cancer Market

3.2. Brazilian Breast Cancer Market

3.2.1 Brazilian Breast Cancer Diagnostic Market

3.2.2 Brazilian Breast Cancer Therapeutic Market

3.3 APAC Countries

3.3.1 APAC Diagnostic Market

3.3.2 APAC Therapeutic Market

3.4 European Breast Cancer Market

3.4.1 European Breast Cancer Diagnostic Market

3.4.2 European Metastatic Breast Cancer Market

 

4. Market Dynamics

4.1 Industry Developments

4.1.1 Introduction of New Drugs & Therapies

4.1.2 Development of Scintimammography for Molecular Breast Imaging

4.1.3 Compounds under Study to Reduce Breast Cancer

4.1.4 Researches on DCIS Prediction

4.2 Growth Drivers

4.2.1 Increasing Use of Tobacco and Alcohol

4.2.2 Increasing Diabetic and Obese Population Worldwide

4.2.3 Rising Healthcare Expenditure

4.2.4 Growing Women Population (Over 45 Years)

4.2.5 Increasing Global Spending on Medicines

4.2.6 Dense Breast Tissue

4.2.7 Exposure to X-Ray and Gamma Radiations

4.2.8 Estrogen-Progestin Therapy (EPT)

4.3 Challenges

4.3.1 Financial Burden of Breast Cancer

4.3.2 Adverse Effects of Aromatase Inhibitors (AI)

 

5. Competitive Landscape

  • Comparison of Drugs
  • Net Income
  • R&D Budget

6. Company Profiles

6.1 Johnson & Johnson

6.1.1 Business Overview

6.1.2 Financial Overview

6.1.3 Business Strategies

6.2 Hologic, Inc.

6.2.1 Business Overview

6.2.2 Financial Overview

6.2.3 Business Strategies

6.3 Roche

6.3.1 Business Overview

6.3.2 Financial Overview

6.3.3 Business Strategies

6.4 Novartis

6.4.1 Business Overview

6.4.2 Financial Overview

6.4.3 Business Strategies

6.5 Siemens AG

6.5.1 Business Overview

6.5.2 Financial Overview

6.5.3 Business Strategies 

 

Stages of Breast Cancer

New Breast Cancer Cases and Deaths in the U.S. (2015E)

The U.S. MBC Market Revenue Model (2011-2015E)

Number of Deaths from Breast Cancer in Brazil 

New Breast Cancer Cases and Deaths in the Europe (2014)

European MBC Market (2011-2015E)

CDK4/6 Inhibitors in Clinical Development

Side Effects of Aromatase Inhibitors Reported by Women

Comparison of Drugs Approved for HR Positive Breast Cancer

Comparison of P13 Kinases in Clinical Development

J&J’s R&D Expenses by Segment (2013 & 2014) 

 

Types of Breast Cancer

Various Biopsy Methods

Global Oncology Drug Spending (2010-2014)

Global Oncology Spending By Region (2014)

Global Breast Cancer Predictive Diagnostic and Drug Technologies (2014 /2019E)

Global Breast Cancer Therapeutic Market (2014 /2018E)

Global Breast Cancer Market by Segments (2014E)

Cases of Breast Cancer in the U.S. by Stage

Breast Cancer Deaths by Age Group in the U.S.

The U.S. Breast Imaging Systems Market (2010-2016E)

The U.S. Digital Mammography Market (2010-2014)

Breast Cancer Therapeutic Market in Major Regions (2014E)

The U.S. Metastatic Breast Cancer Market Revenues (2011-2015E)

Breast Cancer Mortality Rates in Brazil (2008-2014E)

Brazil’s Breast Cancer Imaging Market (2011-2015E)

Brazilian Breast Cancer Drugs Market (2009-2014E)

APAC - Tomography Scanners per Million People (2014)

APAC - MRI Units per Million People (2014)

APAC - Mammography Units per Million Females (2014)

APAC Countries Therapeutic Market Share (2014E)

The European Breast Imaging Systems Market (2013-2018E)

The European Mammography Systems Market (2013-2018E)

European Metastatic Breast Cancer Market Revenues (2011-2015E)

Global Cigarettes Consumption (1910-2014)

Global Diabetic Population (2007-2014E)

Global Obese Population (2009-2014)

Global Healthcare Expenditure Per Capita (2009-2014E)

Global Female Population, Over 45 Years (2008-2014E)

Global Spending on Medicines (2007-2017E)

Net Income Comparison of Leading Companies (2014)

R&D Budgets of Top Companies (2014)

Johnson & Johnson Revenue by Business Segments (2014)

Johnson & Johnson’s Revenue and Net Income (2010-2014)

Hologic’s Revenue by Business Segment (2014)

Hologic’s Revenue and Net Income (2010-2014)

Roche’s Revenue by Business Segments (2014)

Roche’s Sales and Net Income (2010-2014)

Novartis Revenue by Business Segments (2014) 

Novartis Revenues (2010-2014)

Siemens Revenue by Business Segments (2014)

Siemens Revenue and Net Income (2010-2014)